Amarin Corporation plc (AMRN) and Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) Comparison side by side

Both Amarin Corporation plc (NASDAQ:AMRN) and Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amarin Corporation plc 229.21M 29.21 116.44M -0.34 0.00
Eiger BioPharmaceuticals Inc. N/A 0.00 46.78M -3.98 0.00

Table 1 highlights Amarin Corporation plc and Eiger BioPharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Amarin Corporation plc and Eiger BioPharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Amarin Corporation plc -50.80% 827.8% -45.9%
Eiger BioPharmaceuticals Inc. 0.00% -155.6% -85.1%

Volatility and Risk

A 1.31 beta indicates that Amarin Corporation plc is 31.00% more volatile compared to Standard and Poor’s 500. Eiger BioPharmaceuticals Inc.’s 47.00% more volatile than Standard and Poor’s 500 volatility due to the company’s 1.47 beta.

Liquidity

The current Quick Ratio of Amarin Corporation plc is 2 while its Current Ratio is 2.4. Meanwhile, Eiger BioPharmaceuticals Inc. has a Current Ratio of 4.6 while its Quick Ratio is 4.6. Eiger BioPharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Amarin Corporation plc.

Analyst Recommendations

In next table is given Amarin Corporation plc and Eiger BioPharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Amarin Corporation plc 0 0 3 3.00
Eiger BioPharmaceuticals Inc. 0 0 0 0.00

Amarin Corporation plc has a consensus price target of $36, and a 77.08% upside potential.

Insider and Institutional Ownership

Institutional investors held 49.1% of Amarin Corporation plc shares and 86.9% of Eiger BioPharmaceuticals Inc. shares. Insiders held 0.9% of Amarin Corporation plc shares. On the other hand, insiders held about 7.6% of Eiger BioPharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Amarin Corporation plc 9.7% 22.8% 24.22% 567.39% 537.69% 57.9%
Eiger BioPharmaceuticals Inc. 2.07% -1.07% 34.93% 7.63% 48.71% 36.12%

For the past year Amarin Corporation plc’s stock price has bigger growth than Eiger BioPharmaceuticals Inc.

Summary

Amarin Corporation plc beats Eiger BioPharmaceuticals Inc. on 7 of the 10 factors.

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The companyÂ’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.